JP2024518735A5 - - Google Patents
Info
- Publication number
- JP2024518735A5 JP2024518735A5 JP2023564485A JP2023564485A JP2024518735A5 JP 2024518735 A5 JP2024518735 A5 JP 2024518735A5 JP 2023564485 A JP2023564485 A JP 2023564485A JP 2023564485 A JP2023564485 A JP 2023564485A JP 2024518735 A5 JP2024518735 A5 JP 2024518735A5
- Authority
- JP
- Japan
- Prior art keywords
- dose
- aniflorumab
- subject
- administered
- pharmaceutical composition
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2025153759A JP2026012677A (ja) | 2021-04-23 | 2025-09-17 | 抗ｉ型ｉｎｆ受容体抗体アニフロルマブによるループス腎炎の治療 |
Applications Claiming Priority (7)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202163178745P | 2021-04-23 | 2021-04-23 | |
| US63/178,745 | 2021-04-23 | ||
| US202163221986P | 2021-07-15 | 2021-07-15 | |
| US63/221,986 | 2021-07-15 | ||
| US202163270091P | 2021-10-21 | 2021-10-21 | |
| US63/270,091 | 2021-10-21 | ||
| PCT/EP2022/060670 WO2022223771A1 (en) | 2021-04-23 | 2022-04-22 | Treatment of lupus nephritis with anti-type i inf receptor antibody anifrolumab |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2025153759A Division JP2026012677A (ja) | 2021-04-23 | 2025-09-17 | 抗ｉ型ｉｎｆ受容体抗体アニフロルマブによるループス腎炎の治療 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2024518735A JP2024518735A (ja) | 2024-05-02 |
| JP2024518735A5 true JP2024518735A5 (enExample) | 2024-11-12 |
| JP7746407B2 JP7746407B2 (ja) | 2025-09-30 |
Family
ID=81750638
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2023564485A Active JP7746407B2 (ja) | 2021-04-23 | 2022-04-22 | 抗ｉ型ｉｎｆ受容体抗体アニフロルマブによるループス腎炎の治療 |
| JP2025153759A Pending JP2026012677A (ja) | 2021-04-23 | 2025-09-17 | 抗ｉ型ｉｎｆ受容体抗体アニフロルマブによるループス腎炎の治療 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2025153759A Pending JP2026012677A (ja) | 2021-04-23 | 2025-09-17 | 抗ｉ型ｉｎｆ受容体抗体アニフロルマブによるループス腎炎の治療 |
Country Status (16)
| Country | Link |
|---|---|
| US (2) | US20250002590A1 (enExample) |
| EP (2) | EP4595996A3 (enExample) |
| JP (2) | JP7746407B2 (enExample) |
| KR (1) | KR20240001704A (enExample) |
| AU (1) | AU2022260544A1 (enExample) |
| BR (1) | BR112023021514A2 (enExample) |
| CA (1) | CA3216395A1 (enExample) |
| DK (1) | DK4192882T3 (enExample) |
| ES (1) | ES3021882T3 (enExample) |
| FI (1) | FI4192882T3 (enExample) |
| HU (1) | HUE070524T2 (enExample) |
| IL (1) | IL307751B2 (enExample) |
| PL (1) | PL4192882T3 (enExample) |
| PT (1) | PT4192882T (enExample) |
| TW (1) | TW202308691A (enExample) |
| WO (1) | WO2022223771A1 (enExample) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN120392997A (zh) | 2021-04-23 | 2025-08-01 | 阿斯利康(瑞典)有限公司 | 用于皮下注射的抗ifnar1给药方案 |
| CN113278071B (zh) * | 2021-05-27 | 2021-12-21 | 江苏荃信生物医药股份有限公司 | 抗人干扰素α受体1单克隆抗体及其应用 |
| GB202402824D0 (en) * | 2024-02-28 | 2024-04-10 | Astrazeneca Ab | Treatment of chronic kidney disease |
Family Cites Families (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7662381B2 (en) | 2004-06-21 | 2010-02-16 | Medarex, Inc. | Interferon alpha receptor 1 antibodies and their uses |
| KR20160070165A (ko) | 2008-02-08 | 2016-06-17 | 메디뮨 엘엘씨 | Ｆｃ 리간드 친화성이 감소된 항-ＩＦＮＡＲ１ 항체 |
| CA2772921A1 (en) | 2009-09-03 | 2011-03-10 | Medimmune, Llc | Type 1 interferon diagnostic |
| TWI452136B (zh) * | 2010-11-17 | 2014-09-11 | 中外製藥股份有限公司 | A multiple specific antigen-binding molecule that replaces the function of Factor VIII in blood coagulation |
| US8790651B2 (en) * | 2011-07-21 | 2014-07-29 | Zoetis Llc | Interleukin-31 monoclonal antibody |
| KR102320059B1 (ko) * | 2012-06-13 | 2021-11-01 | 아스트라제네카 아베 | 항-i형 인터페론 수용체(ifnar) 항체에 대한 고정 투여 계획 |
| RS64263B1 (sr) * | 2015-08-19 | 2023-07-31 | Astrazeneca Ab | Stabilna anti-ifnar1 formulacija |
| EP3448427A1 (en) * | 2016-04-29 | 2019-03-06 | CureVac AG | Rna encoding an antibody |
| CN106243226B (zh) | 2016-08-05 | 2019-02-12 | 北京智仁美博生物科技有限公司 | 抗人ifnar1的抗体及其用途 |
| CN120392997A (zh) * | 2021-04-23 | 2025-08-01 | 阿斯利康(瑞典)有限公司 | 用于皮下注射的抗ifnar1给药方案 |
| CN113278070B (zh) | 2021-04-25 | 2022-06-14 | 福州迈新生物技术开发有限公司 | 抗ck17蛋白单克隆抗体及其细胞株、制备方法和应用 |
| CN113527490B (zh) * | 2021-07-13 | 2022-03-01 | 江苏荃信生物医药股份有限公司 | 一种抗人ifnar1单克隆抗体浓缩溶液的制备方法 |
| CN113621063A (zh) * | 2021-08-02 | 2021-11-09 | 江苏荃信生物医药有限公司 | 降低单克隆抗体生产中宿主细胞蛋白含量的亲和纯化方法 |
-
2022
- 2022-04-22 CA CA3216395A patent/CA3216395A1/en active Pending
- 2022-04-22 FI FIEP22724712.9T patent/FI4192882T3/fi active
- 2022-04-22 AU AU2022260544A patent/AU2022260544A1/en active Pending
- 2022-04-22 PL PL22724712.9T patent/PL4192882T3/pl unknown
- 2022-04-22 ES ES22724712T patent/ES3021882T3/es active Active
- 2022-04-22 WO PCT/EP2022/060670 patent/WO2022223771A1/en not_active Ceased
- 2022-04-22 DK DK22724712.9T patent/DK4192882T3/da active
- 2022-04-22 US US18/556,733 patent/US20250002590A1/en active Pending
- 2022-04-22 KR KR1020237040114A patent/KR20240001704A/ko active Pending
- 2022-04-22 TW TW111115513A patent/TW202308691A/zh unknown
- 2022-04-22 IL IL307751A patent/IL307751B2/en unknown
- 2022-04-22 HU HUE22724712A patent/HUE070524T2/hu unknown
- 2022-04-22 PT PT227247129T patent/PT4192882T/pt unknown
- 2022-04-22 JP JP2023564485A patent/JP7746407B2/ja active Active
- 2022-04-22 EP EP25158131.0A patent/EP4595996A3/en active Pending
- 2022-04-22 BR BR112023021514A patent/BR112023021514A2/pt unknown
- 2022-04-22 EP EP22724712.9A patent/EP4192882B1/en active Active
- 2022-04-22 US US17/660,340 patent/US20220348669A1/en active Pending
-
2025
- 2025-09-17 JP JP2025153759A patent/JP2026012677A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2024518735A5 (enExample) | ||
| AU2020266593B2 (en) | Methods for treating or preventing asthma by administering an IL-33 antagonist | |
| WO2023209036A1 (en) | Methods for treating bullous pemphigoid using fcrn antagonists | |
| ES3021882T3 (en) | Treatment of lupus nephritis with anti-type i inf receptor antibody anifrolumab | |
| EP4612183A1 (en) | Methods for treating hand and foot dermatitis by administering an il-4r antagonist | |
| JP2024519196A5 (enExample) | ||
| KR20240000557A (ko) | 피부 홍반 루푸스의 치료 | |
| JP2024527001A5 (enExample) | ||
| JP2024516886A5 (enExample) | ||
| TW202337913A (zh) | 每週投予一次ｆｖｉｉｉ模擬雙特異性抗體之方法 | |
| KR20240006549A (ko) | 전신 홍반성 루푸스 환자에서 1형 인터페론 수용체 스테로이드 절약의 억제제 | |
| US20260070995A1 (en) | Methods for treating bullous pemphigoid by administering an il-4r antagonist | |
| TW202345897A (zh) | 每月投予一次ｆｖｉｉｉ模擬雙特異性抗體之方法 | |
| TW202345896A (zh) | 每兩週投予一次ｆｖｉｉｉ模擬雙特異性抗體之方法 | |
| CN120344259A (zh) | 狼疮的治疗 | |
| CN117157326A (zh) | 抗i型inf受体抗体阿尼鲁单抗治疗狼疮性肾炎 | |
| EP4731680A1 (en) | Methods of administering fviii mimetic bispecific antibodies once every second month | |
| CN121127499A (zh) | 狼疮的治疗 | |
| CN118786147A (zh) | 每月一次施用fviii模拟双特异性抗体的方法 | |
| WO2024112935A1 (en) | Methods for improving bone growth by administering an il-4r antagonist | |
| CN117337305A (zh) | 系统性红斑狼疮患者中的1型干扰素受体抑制剂类固醇节制 | |
| EA052183B1 (ru) | Лечение кожной красной волчанки |